SAN DIEGO, March 1 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place on March 8, 2010, 4:00 p.m. Eastern Time.
Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
A live audio webcast of this presentation will be accessible on the Company's website at www.optimerpharma.com, under the investors section. A replay of this presentation will be available at the same location for thirty days following the meeting.
Advertisement
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is a new class of antibiotics with narrow spectrum bactericidal activity targeted at the site of infection. Recently reported positive top-line results from the second Phase 3 trial confirmed the results from the first Phase 3 trial regarding fidaxomicin's safety and efficacy in patients with Clostridium difficile infection. Optimer has also successfully completed two Phase 3 trials with Pruvel(TM), for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts Optimer Pharmaceuticals, Inc. Christina Donaghy, Corporate Communications Manager John D. Prunty, Chief Financial Officer & VP Finance 858-909-0736 Porter Novelli Life Sciences Jason I. Spark, Vice President 619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
